SCHEMBL6865980

SCHEMBL6865980

Clc1ncnc2c1c(I)cn2C1CCNCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 7/20 0.50
▸ SLC29A1 Q99808 1/20 0.50
▸ FGR P09769 1/20 0.43
▸ EPHA1 P21709 1/20 0.43
▸ TXK P42681 1/20 0.43
▸ FRK P42685 1/20 0.43
▸ PTK6 Q13882 1/20 0.43
▸ SRC P12931 8/20 0.42
▸ LCK P06239 3/20 0.42
▸ TEK Q02763 1/20 0.42
▸ EGFR P00533 4/20 0.41
▸ ABL1 P00519 4/20 0.40
▸ ABL2 P42684 3/20 0.40
▸ MTOR P42345 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ DAPK3 O43293 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ PAK4 O96013 1/20 0.36
▸ FYN P06241 1/20 0.36
▸ CSF1R P07333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15739516 0.92 SRC (0.50) ADKSLC29A1FGREPHA1TXK
SCHEMBL16236390 0.90 ADK (0.54) ADKSLC29A1SRCLCKEGFR
SCHEMBL29484542 0.90 ADK (0.54) ADKSLC29A1SRCLCKEGFR
Trifluoroacetic Acid SCHEMBL18044662 0.89 ADK (0.44) ADKSLC29A1FGREPHA1TXK
SCHEMBL1939761 0.87 ADK (0.52) ADKSLC29A1SRCLCKTEK
SCHEMBL401328 0.87 ADK (0.52) ADKSLC29A1SRCLCKEGFR
Tert-Butyl Formate SCHEMBL27864305 0.87 ADK (0.42) ADKSLC29A1FGREPHA1TXK
SCHEMBL30373169 0.86 ADK (0.51) ADKSLC29A1SRCLCKTEK
SCHEMBL16236685 0.86 ADK (0.51) ADKSLC29A1SRCLCKTEK
SCHEMBL22086530 0.86 ADK (0.51) ADKSLC29A1SRCLCKTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-12-05 — — US disclosed
EP-3472165-B1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2023-09-06 — — EP disclosed
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-04-06 — — US disclosed
US-11491158-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-11-08 — — US disclosed
CN-109311894-B N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors 内尔维阿诺医学科学有限公司 2022-03-22 — — CN disclosed
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-05-06 — — US disclosed
US-10918642-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-02-16 — — US disclosed
US-20200121686-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-04-23 — — US disclosed
US-10561660-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-02-18 — — US disclosed
US-20190201406-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-07-04 — — US disclosed
EP-3472165-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2019-04-24 — — EP disclosed
WO-2017220477-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-12-28 — — WO disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 — — US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI ADK 1047/4885SLC29A1 700/4885FGR 283/4885
US-20190201406-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885
US-11491158-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885
US-10918642-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885
US-20200121686-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885
US-10561660-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885FGR 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback